FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213084839> ?p ?o ?g. }

• W4213084839 endingPage "282" @default.
• W4213084839 startingPage "282" @default.
• W4213084839 abstract "282 Background: Active surveillance is a common management strategy for men with low-risk prostate cancer. However, there is some concern that delaying definitive therapy could lead to progressive disease and a missed opportunity to cure the cancer. We sought to study the impact of Gleason grade progression on the risk of metastases and prostate cancer-specific mortality (PCSM). We then sought to compare the risks of PCSM with the risk of competing mortality in this real-world cohort of men on active surveillance. Methods: This was a retrospective population-based cohort study using patient records from the Veterans Heath Administration Informatics and Computing Infrastructure of patients with a diagnosis of low-risk prostate cancer from January 1, 2001, to December 31, 2015, who were managed with active surveillance. Follow-up extended through March 31, 2020. Low-risk prostate cancer was defined as International Society of Urologic Pathology grade group (GG) 1, clinical tumor stage 2A or lower, PSA level of 10 ng/dL or lower. Active surveillance was defined as no definitive treatment within the first year after diagnosis with at least 1 additional re-staging biopsy after diagnostic biopsy. We identified men with pathologic upgrading to ≥GG2 and ≥GG3. We calculated the cumulative incidence of metastases, PCSM, and non-cancer mortality for men with and without pathologic upgrading. Results: The cohort included 8562 men with low-risk PC. Pathologic upgrading to ≥GG2 and ≥GG3 occurred in 3227 and 1200 men, respectively. For all patients, the 8-year cumulative incidence of metastases and PCSM was 0.8% (95% CI: 0.6-1.0%) and 0.4% (CI:0.3-0.6%), respectively. Pathologic upgrading to ≥GG2 was associated with an increased risk of metastases at 8 years (1.2% vs 0.5%, p < 0.001). Pathologic upgrading to ≥GG3 was also associated with an increased risk of metastases at 8 years (2.7% vs 0.5%, p < 0.001). In contrast, pathologic upgrading to ≥GG2 was not associated with an increased risk of PCSM at 8 years (0.5% vs 0.4%, p = 0.793). Similarly, pathologic upgrading to ≥GG3 was not associated with an increased risk of PCSM at 8 years (0.7% vs 0.4%, p = 0.82). The 8-year cumulative incidence of non-cancer mortality for all patients was 6.5% (95% CI:5.9-7.1%). Overall, the risk of non-cancer mortality was 16.25 (6.5/0.4) times higher than the risk of PCSM, regardless of upgrading status. Conclusions: For men with low-risk PC on active surveillance, pathologic upgrading was associated with a small increased risk of metastases but no increased risk of death from prostate cancer. Regardless of upgrading status, the risk of non-cancer mortality was substantially higher than the risk of PCSM. Future work is required to better tailor the intensity of follow up for surveillance protocols for men at risk of competing mortality." @default.
• W4213084839 created "2022-02-24" @default.
• W4213084839 creator A5026311650 @default.
• W4213084839 creator A5030086472 @default.
• W4213084839 creator A5031828323 @default.
• W4213084839 creator A5044071754 @default.
• W4213084839 creator A5089442996 @default.
• W4213084839 creator A5091329688 @default.
• W4213084839 date "2022-02-20" @default.
• W4213084839 modified "2023-09-27" @default.
• W4213084839 title "Disease progression and competing mortality for men undergoing active surveillance for low-risk prostate cancer." @default.
• W4213084839 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.282" @default.
• W4213084839 hasPublicationYear "2022" @default.
• W4213084839 type Work @default.
• W4213084839 citedByCount "0" @default.
• W4213084839 crossrefType "journal-article" @default.
• W4213084839 hasAuthorship W4213084839A5026311650 @default.
• W4213084839 hasAuthorship W4213084839A5030086472 @default.
• W4213084839 hasAuthorship W4213084839A5031828323 @default.
• W4213084839 hasAuthorship W4213084839A5044071754 @default.
• W4213084839 hasAuthorship W4213084839A5089442996 @default.
• W4213084839 hasAuthorship W4213084839A5091329688 @default.
• W4213084839 hasConcept C120665830 @default.
• W4213084839 hasConcept C121332964 @default.
• W4213084839 hasConcept C121608353 @default.
• W4213084839 hasConcept C126322002 @default.
• W4213084839 hasConcept C143998085 @default.
• W4213084839 hasConcept C167135981 @default.
• W4213084839 hasConcept C2776141087 @default.
• W4213084839 hasConcept C2776235491 @default.
• W4213084839 hasConcept C2779134260 @default.
• W4213084839 hasConcept C2780192828 @default.
• W4213084839 hasConcept C2908647359 @default.
• W4213084839 hasConcept C29456083 @default.
• W4213084839 hasConcept C61511704 @default.
• W4213084839 hasConcept C71924100 @default.
• W4213084839 hasConcept C72563966 @default.
• W4213084839 hasConcept C88879693 @default.
• W4213084839 hasConcept C99454951 @default.
• W4213084839 hasConceptScore W4213084839C120665830 @default.
• W4213084839 hasConceptScore W4213084839C121332964 @default.
• W4213084839 hasConceptScore W4213084839C121608353 @default.
• W4213084839 hasConceptScore W4213084839C126322002 @default.
• W4213084839 hasConceptScore W4213084839C143998085 @default.
• W4213084839 hasConceptScore W4213084839C167135981 @default.
• W4213084839 hasConceptScore W4213084839C2776141087 @default.
• W4213084839 hasConceptScore W4213084839C2776235491 @default.
• W4213084839 hasConceptScore W4213084839C2779134260 @default.
• W4213084839 hasConceptScore W4213084839C2780192828 @default.
• W4213084839 hasConceptScore W4213084839C2908647359 @default.
• W4213084839 hasConceptScore W4213084839C29456083 @default.
• W4213084839 hasConceptScore W4213084839C61511704 @default.
• W4213084839 hasConceptScore W4213084839C71924100 @default.
• W4213084839 hasConceptScore W4213084839C72563966 @default.
• W4213084839 hasConceptScore W4213084839C88879693 @default.
• W4213084839 hasConceptScore W4213084839C99454951 @default.
• W4213084839 hasIssue "6_suppl" @default.
• W4213084839 hasLocation W42130848391 @default.
• W4213084839 hasOpenAccess W4213084839 @default.
• W4213084839 hasPrimaryLocation W42130848391 @default.
• W4213084839 hasRelatedWork W1899936169 @default.
• W4213084839 hasRelatedWork W1980245127 @default.
• W4213084839 hasRelatedWork W2106003470 @default.
• W4213084839 hasRelatedWork W2142658264 @default.
• W4213084839 hasRelatedWork W2274531947 @default.
• W4213084839 hasRelatedWork W2433835599 @default.
• W4213084839 hasRelatedWork W2536626477 @default.
• W4213084839 hasRelatedWork W2610820427 @default.
• W4213084839 hasRelatedWork W2999207890 @default.
• W4213084839 hasRelatedWork W3021867774 @default.
• W4213084839 hasVolume "40" @default.
• W4213084839 isParatext "false" @default.
• W4213084839 isRetracted "false" @default.
• W4213084839 workType "article" @default.